Chapter 11: Drug Therapy During Pregnancy and Breastfeeding

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to today's Deep Dive.

We have a really highly specific mission today.

We are chapter 11 from Land's Pharmacology for Nursing Care, the 12th edition.

Right, focusing on drug therapy during pregnancy and breastfeeding.

Exactly.

So if you are a nursing student looking at a syllabus right now, you know, trying to figure out how to navigate this material for your exam, consider this your ultimate study companion from the Last Minute Lecture team.

We are definitely going to translate a massive amount of dense drug data today.

Yeah, we're putting it into a logical progression so you can actually understand the clinical decisions being made at the bedside.

Because, I mean, treating patients during pregnancy and lactation, it involves a clinical gray area that we just don't usually see in other areas of medicine.

You have two patients simultaneously, right?

Right, the person carrying the pregnancy and the developing fetus.

Or the nursing infant, yeah.

And you have to treat the maternal condition effectively without harming the development of the child.

And while the defining characteristic of this area of pharmacology is a severe, almost terrifying lack of reliable data.

Okay, let's unpack this because that data void is so interesting.

It's not like pregnant patients aren't taking medication.

I mean, the text notes that about two -thirds of pregnant patients take at least one medication.

Oh, easily.

And a lot of them take way more than that.

Right.

They could be taking drugs to treat pregnancy -related conditions like severe nausea, preeclampsia,

constipation.

Or they might have chronic conditions like asthma, epilepsy, diabetes.

Plus, we have to account for acute infections, cancer,

and sadly, potential drugs of abuse.

Yeah, the necessity of treatment doesn't just pause for gestation.

The prescriber and the nurse are constantly forced to weigh the benefits of a drug against the risks to the fetus.

It's a huge balancing act.

It really is.

The textbook actually uses asthma as a perfect illustration of this balance.

If a pregnant patient has uncontrolled asthma, the incidence of stillbirth literally doubles.

Doubles.

Doubles.

So in that scenario, the uncontrolled disease state is exponentially more dangerous to the fetus than the medication required to manage the asthma.

So you're basically walking a pharmacological tightrope blindfolded.

You're forced to act, but the dilemma is that you are weighing those risks and benefits without a complete picture of the drug's safety profile.

Exactly.

And the reason for that blind spot, it just comes down to basic medical ethics.

I mean, we simply cannot run randomized, controlled clinical trials where we intentionally give a drug to a pregnant person.

Just to see if it causes a congenital anomaly in their baby.

That would be horrific.

Right.

Ethically impossible.

So because of that, the medical community relies heavily on retrospective data.

We have to gather information after the fact.

After the fact.

Meaning, like, looking at clinical histories.

Yeah.

We look at the clinical histories of people who have had children with congenital anomalies and we compare them to those who haven't.

The National Birth Defects Prevention Study is a major source of this kind of epidemiological data.

And there are also FDA listed pregnancy registries, right?

Yes.

Those are crucial.

Yeah.

They're basically tracking systems for patients who, because of a severe illness, had absolutely no choice but to take a specific drug during their pregnancy.

Right.

And the registries monitor the outcomes of those specific pregnancies to piece together a safety profile over time.

But that feels like such a slow reactionary way to build clinical guidelines.

It is, but it's what we have.

And since we are often prescribing with incomplete data, the absolute minimum we need to understand is how the pregnant body physically alters the pathway of the drugs we do administer.

Right.

The pharmacokinetic.

Exactly.

Gestation profoundly changes a patient's pharmacokinetics.

How the body absorbs, distributes, metabolizes, and excretes medications.

Okay.

So let's trace a drug through those altered bodily systems, starting with elimination.

The mother's blood volume expands by up to 50 % to support the placenta and the fetus.

Which is a massive physical change.

Yeah.

And that massive increase in fluid volume basically forces the kidneys into overdrive.

By the third trimester, renal blood flow basically doubles, which drastically increases the glomerular filtration rate, the GFR.

And that increased filtration rate means the kidneys are flushing out substances at a highly accelerated pace.

Any medication that is primarily cleared by the kidneys is going to leave the body much faster.

Which means the textbook's example of lithium makes total sense.

Right.

Lithium is the classic example here.

The elimination rate of lithium increases by 100 % during pregnancy.

So if you are the nurse caring for a pregnant patient with bipolar disorder who is prescribed lithium, you have to anticipate that physical change.

Because if the provider keeps the dosage exactly the same as it was prior to pregnancy,

the patient's blood levels are going to plummet into a subtherapeutic range.

Exactly.

They will likely need a significant dosage increase just to maintain the exact same clinical effect.

Wait, the liver undergoes functional changes as well, right?

Does that also speed things up?

It does, yeah.

Driven by hormonal shifts, hepatic metabolism actually increases for several specific medications.

A major class affected here is anti -seizure medications.

Like phenytoin.

Phenytoin, carbamazepine, and valproic acid.

The liver breaks these down more rapidly during pregnancy.

So a nurse monitoring a patient with epilepsy needs to be keenly aware that their medication dosages may also need to increase to prevent breakthrough seizures.

Okay, so increased blood volume and increased liver enzymes generally mean the body clears drugs faster, so you need doses.

But the gastrointestinal tract does the exact opposite.

Right, the GI tract slows everything down.

Which is wild.

Wait, if the patient's body mass is increasing, shouldn't they automatically need more of every drug?

It's wild that because their GI tract slows down, they might actually need less of certain medications to avoid toxicity.

It is completely counterintuitive, but yes, because of the hormonal changes of pregnancy, the tone and motility of the bowel decrease.

And that physical slowdown introduces an entirely different pharmacological challenge.

Because the drug just sits there.

Exactly.

Because intestinal transit time is increased, an oral drug sits in the GI tract for a much longer period.

This provides more time for the drug to be absorbed into the systemic circulation.

And crucially, it also drastically prolongs a process called enterohepatic recirculation.

Oh, I always picture enterohepatic recirculation like

a piece of luggage on an airport baggage carousel.

That's a great analogy.

Right, so normally a drug is processed by the liver, sent to the GI tract in bile, and then exits the body.

It gets pulled off the carousel.

But because the pregnant patient's GI tract is moving so sluggishly, that drug gets reabsorbed through the intestinal wall back into the bloodstream.

The luggage just keeps missing the exit and making another loop.

That is an excellent way to visualize the mechanism.

And because the drug keeps looping back into the bloodstream, blood levels can rise unexpectedly.

So for medications heavily impacted by enhanced absorption or prolonged recirculation, the nurse might actually need to anticipate a dosage decrease to prevent toxic buildup.

Okay, so once a drug is in the maternal bloodstream, it eventually reaches the placenta.

And I feel like there is this persistent myth that the placenta is some kind of magical impenetrable shield protecting the fetus.

Oh, definitely.

But fundamentally, the placenta is just a biological membrane.

The standard rules of cellular transport still apply.

Meaning lipid solubility is key.

Right.

Drugs that are highly lipid soluble will slide right through the placental membrane and into the fetal circulation with ease.

Conversely, drugs that are highly polar, ionized, or tightly bound to maternal blood proteins will struggle to cross.

But the overarching clinical safety rule for nursing students to internalize is just assume that all drugs cross the placenta to some extent.

Always assume they cross.

And when those drugs do cross, we have to look at the damage they can do.

I feel like everyone immediately thinks of birth defects.

But adverse drug reactions during pregnancy cover a much wider spectrum.

Right.

Oh, much wider.

A drug can threaten the maternal patient directly.

It can threaten the stability of the pregnancy itself.

Or it can harm the neonate afterbirth in ways that have nothing to do with physical deformities.

What's a good example of a threat to the pregnancy state itself?

A prime example is mesoprostol.

It's a medication often to protect the stomach lining of patients taking heavy doses of NSAIDs.

But mesoprostol fundamentally alters cervical tone and stimulates uterine contractions.

Oh, so taking it during pregnancy can trigger a spontaneous abortion.

Exactly.

And aspirin presents a different risk.

If taken near term, aspirin profoundly suppresses platelet aggregation, which drastically increases the risk of severe uncontrolled maternal bleeding during childbirth.

And then we have threats specific to the fetus in the newborn, like warfarin, the anticoagulant.

That crosses the placenta and can cause catastrophic fetal hemorrhage.

Right.

And if a patient takes central nervous system depressants, like benzodiazepines, late in their pregnancy, the infant is born with those depressants still in their system.

Which leads to floppy infant syndrome.

Yes.

The neonate is born in a hypotonic state.

Because their central nervous system is depressed by the benzos, they really struggle to regulate their own breathing and maintain their blood sugar.

It leads to severe respiratory complications and hypoglycemia.

This connects directly to the issue of maternal drug dependence too.

If a patient is regularly using dependence producing substances like heroin, barbiturates, or alcohol,

the fetus is basically receiving a steady continuous supply of that substance through the placental blood flow.

Right.

The fetus develops a physical dependence right alongside the mother.

And the crisis occurs the exact moment the cord is cut.

That steady supply is instantly severed and the infant is thrust into a severe withdrawal syndrome.

And a neonatal nurse is going to observe those classic withdrawal signs, the distinct high pitched, shrill cry, vomiting, tremors, extreme irritability.

It's agonizing to watch.

To prevent fatal complications, the medical team actually has to administer progressively smaller doses of the dependence producing drug or safe substitute to gradually wean the infant.

It's essentially a spillover effect.

Treating a maternal condition spills over into the infant's system.

Another really clear example of that is using powerful opioid pain relievers during labor and delivery.

Right, because you are treating the mother's acute severe pain, but those opioids cross the placenta in the final moments before birth.

And they physically depress the infant's respiratory drive just as they are supposed to be taking their first independent breaths.

The nurse has to monitor that newborn's respirations incredibly closely.

Exactly.

But while all of these systemic adverse effects are dangerous, the textbook emphasizes that the drug effect of greatest clinical concern is teratogenesis.

Right, from the Greek root teratis meaning monster.

Yes, it refers to a substance producing congenital anomalies or severe birth defects.

But the essential concept here for students to grasp is that a teratogen's destructive power is dictated almost entirely by when the fetus is exposed to it.

It's all about the timeline of cellular development.

The text breaks gestational vulnerability down into three major stages.

Stage one is the preimplantation or prezomite period.

This is the very beginning spanning from conception through the second week.

And the mechanism here is fascinating because it operates on an all or nothing principle.

Okay, here's where it gets really interesting.

So if a patient has a wild weekend before they know they're pregnant,

it's literally all or nothing.

There's no in -between damage during those first two weeks.

That's exactly right.

During those first two weeks, the embryo or the conceptus is just a tiny cluster of rapidly dividing undifferentiated cells.

Because they haven't specialized into specific organs yet, they are incredibly resilient.

So if there's a sublethal dose.

Right, if they're exposed to a sublethal dose of a teratogen, a few cells might die.

But the remaining undifferentiated cells simply divide and replace them.

The conceptus recovers fully with no gross anatomical defects.

But if the dose is sufficiently high,

it overwhelms that cellular recovery process,

resulting in the death of the conceptus and a spontaneous abortion,

total recovery or total loss.

Exactly.

But once we enter stage two, that resilience completely vanishes.

Stage two is the embryonic period covering weeks three through eight.

This is the definitive danger zone for gross malformations.

Because this is when organogenesis is happening.

Right.

The basic shapes, structures and frameworks of all the internal organs are being established.

The cells are no longer undifferentiated.

They have very specific assignments.

So if a teratogen disrupts cellular division during say week four or five, the cells responsible for forming the palate or the heart valves might fail to develop.

The fetus can't just replace them anymore.

Exactly.

This is when exposures lead to severe anatomical defects like cleft palate, club foot or structural heart deformities.

And then by the time we reach stage three, the fetal period spanning from week nine all the way to term, the gross anatomical structures are mostly complete.

The organs are formed.

They just need to grow.

Right.

So teratogens introduced during the second and third trimesters generally disrupt function rather than gross anatomy.

The major exception there is the brain.

Yes.

The central nervous system is developing and wiring itself at an astonishing rate throughout the entire pregnancy.

So exposure to teratogens in the later stages primarily manifests as functional and behavioral abnormalities.

Like learning deficits or developmental delays later in the child's life.

Precisely.

Understanding that timeline really helps us see how damage occurs.

But proving that a specific drug caused a specific defect is notoriously difficult.

I mean, congenital anomalies occur naturally in about

pregnancies without any drug exposure at all.

Yes, the 3 % baseline.

Right.

So when a defect happens, separating a natural occurrence from a drug -induced injury is incredibly complex, especially since, as we said, we can't test drugs on pregnant humans.

And relying on animal testing to bridge that gap has proven disastrous.

The medical community learned this the hard way through the thalidomide tragedy.

Yeah, that was in the 1950s, right?

Prescribed for morning sickness.

Right.

In animal trials, pregnant mice and rats showed absolutely no adverse effects.

The drug appeared perfectly safe.

But animal metabolic pathways are not identical to human ones.

And when human patients took thalidomide during that critical stage two window of organogenesis?

Approximately 30 % of their babies were born with profound gross malformations, most notably focumelia, which is a severe shortening or absence of the limbs.

The core pharmacological rule born from that tragedy is that a lack of teratogenicity in animals does not guarantee safety in humans.

In identifying teratogens is further complicated by the delay problem.

Some drug -induced injuries don't manifest until years after birth.

A classic example from the text is Dithylstilbestrol, or DES.

Yes, a synthetic estrogen given to prevent miscarriages.

The drug altered the cellular development of the fetal reproductive tract, but the damage was microscopic.

Right.

It wasn't until those offspring reached puberty, like 18 years later, that the cellular alterations manifested as a rare form of vaginal cancer.

Wait, 18 years.

18 years.

And behavioral teratogens are just as insidious.

A functional defect in the brain's wiring caused by a drug in the third trimester might remain completely invisible until that child enters elementary school and displays profound learning disabilities.

It's like playing detective a decade after the crime was committed, trying to tie a child's learning delay to a single pill taken in the second trimester.

Exactly.

Which is why the criteria for officially classifying a drug as a teratogen are incredibly strict.

First, it must cause a characteristic recognizable set of malformations.

Second, it must act only during a specific documented window of gestational vulnerability.

And third, the incidence of those malformations must scale mathematically with the dose and of the exposure.

Even then, the risk of malformation is usually only about 10%.

Let's break down some of the proven culprits from table 11 .1 that nursing students need to memorize.

We already mentioned the anti -seizure medications.

Yes, carbamazepine and belproic acid they interfere with early cell division and are strongly linked to neural tube defects, where the spinal cord fails to close properly.

And antimiprobials carry specific risks too.

Tetracycline, the antibiotic,

binds aggressively to calcium.

So if taken during pregnancy, it incorporates itself right into the developing fetal bones and teeth.

Causing permanent tooth discoloration and skeletal anomalies.

Another one that students often miss is the risk associated with blood pressure medications, specifically ACE inhibitors.

Right.

If a patient takes an ACE inhibitor during the second or third trimester, it blocks a hormone called angiotensin II, which is essential for fetal kidney function.

And the cascade effect there is severe.

The fetal kidneys fail and stop producing urine.

Now, fetal urine makes up a massive portion of the amniotic fluid.

So without that fluid acting as a pressurized cushion, the walls of the uterus actually compress the growing fetus, preventing the skull from expanding and developing properly skull hypoplasia.

Exactly.

Vitamin A is another critical one.

High dose vitamin A derivatives like the acne medication isotretinoin are highly potent causing multiple severe defects across the central nervous system and the cardiovascular system.

And then we have NSAIDs like ibuprofen.

Right.

Because the fetal heart has a specialized blood vessel called the ductus arteriosus that allows blood to bypass the inactive lungs.

This vessel is kept open by hormones called prostaglandins.

And since the entire mechanism of action for NSAIDs is to block prostaglandin synthesis, taking an NSAID can cause that vital vessel to close prematurely while the fetus is still in the uterus.

Leading to severe fetal heart failure.

Wow.

With all these complex mechanisms and risks, nurses and prescribers really need clear guidance at the bedside.

For decades, the FDA used a simple letter system on drug labels.

Categories A, B, C, D, and X.

Which was abandoned in 2014.

But why get rid of the letter system?

A, B, C, D, X seems so easy to memorize.

Because it was dangerously reductive.

A single letter doesn't give a nurse the context needed to actually educate a patient.

I mean, if a drug is a category D, does it cause heart defects or learning delays?

Does it happen in a week four or week 34?

Ah, the letter system couldn't answer those questions.

Exactly.

So the FDA replaced it with the Pregnancy and Lactation Labeling Rule, or the PLLR.

And the PLLR requires drug manufacturers to provide detailed narrative summaries on the label.

Divided into three specific sections.

Right.

The pregnancy section details the actual risks based on human and animal data, and lists any available pregnancy registries.

The lactation section details how much of the drug gets into breast milk, and how it affects the infant.

And the third section is Females and Males of Reproductive Potential.

That provides crucial guidance on whether pregnancy testing is required before starting the drug, what kind of contraception is necessary, and whether the drug impacts future fertility.

It forces the provider to look at the actual data rather than just relying on a letter grade.

And that detailed data is vital for minimizing risk.

Which brings us to the primary nursing implication here.

Comprehensive medication reconciliation.

You have to ask the patient about every single substance they take.

Not just prescriptions.

Over -the -counter pain relievers.

Obl remedies.

Nutritional supplement.

Right.

As we saw with vitamin A, over -the -counter supplements can be highly teratogenic.

If a high -risk drug is identified, the goal is always to substitute it with a safer alternative.

But there are tragic, unavoidable clinical scenarios, right?

Like a pregnant patient requiring highly toxic chemotherapy for an aggressive cancer.

Yes.

In situations where a teratogenic drug cannot be ethically withheld from the mother, termination of the pregnancy must be openly considered and discussed.

And these high -stakes risks make patient teaching a critical nursing responsibility.

Statistically, about 50 % of all pregnancies are unintended.

You cannot assume a patient isn't pregnant just because they aren't planning to be.

Exactly.

Any patient of reproductive age who has prescribed a known teratogen must receive thorough education on the risks.

And they must be instructed to use at least one highly reliable form of birth control while on the medication.

But accidental exposures still happen.

What happens if a patient accidentally takes a teratogen?

If a patient realizes they are pregnant while actively taking a teratogen, the clinical response relies entirely on establishing a timeline.

You must determine exactly when the drug was taken and exactly when the pregnancy began.

Okay, so if the exposure occurred outside of weeks 3 -8, that critical organogenesis window, the nurse's role is basically to reassure the patient.

Remind them of the 3 % baseline rate of natural congenital anomalies, so they understand the risk of a drug -induced gross malformation is minimal and any minor anomaly isn't automatically blamed on that single drug exposure.

However, if the exposure occurred right in the middle of weeks 3 -8, the protocol escalates.

The provider must consult authoritative FDA databases to determine the specific malformations associated with that drug.

And then they'll order at least two targeted ultrasound scans to physically assess the fetus for structural injury.

Right, to guide further clinical decisions.

Okay, so let's shift our focus to the postpartum period.

The infant is born, but the pharmacological considerations continue into section 7 of the text.

Breastfeeding.

We have to examine how medications transfer into breast milk.

The physiological rules here basically mirror placental transfer.

The membranes of the mammary glands allow highly lipid -soluble drugs to pass directly into the breast milk with ease.

But drugs that are highly polar, ionized, or bound to maternal proteins largely remain in the maternal bloodstream and are excluded from the milk.

Correct.

But again, the safest clinical assumption is that most drugs will be detected in breast milk to some degree.

Usually a concentration in milk is so low it doesn't cause a pharmacological effect in the infant.

But when a nurse needs definitive proof of safety, the ultimate bedside resource is the LACMED database.

Hosted by the National Library of Medicine, LACMED provides the most comprehensive, peer -reviewed data on drug levels in breast milk and the observed effects on nursing infants.

The textbook provides clear categories of risk for breastfeeding.

Certain drugs are strictly contraindicated.

This includes controlled substances, anti -cancer agents, and immunosuppressants.

And specific standard medications too, right?

Like lithium, etanolol, nicotine.

Yes.

And if a nursing patient requires a radioactive compound for a diagnostic scan, they must temporarily pump and discard their milk until the radioactivity clears.

On the safer side of the spectrum, we have the drugs of choice.

If a nursing patient has acute pain, acetaminophen and ibuprofen are the preferred analgesics.

For depression, sertraline is heavily studied and considered safe.

For bacterial infections, penicillins and macrolides are the go -to anti -microbials.

And a fascinating pharmacological nuance occurs with anticoagulants.

Warfarin and unfractionated heparin are both considered safe during breastfeeding, but for entirely different reasons.

Right, heparin is a massive, highly polar molecule.

It is physically too large to cross the mammary membranes in significant amounts.

Plus, it has zero oral bioavailability.

So even if a tiny amount transferred into the milk, the infant's stomach acid would completely destroy the massive molecule before it could ever be absorbed into their bloodstream.

Exactly.

And for medications that do cross into the milk, the nurse must teach the patient how to time their doses to minimize infant exposure.

So what does this all mean for the patient?

I like to picture the concept of timing the tide.

You administer the medication right as the tide of breastfeeding goes out.

That's a perfect analogy.

Dosing immediately after breastfeeding is the ideal strategy.

This maximizes the window of time the mother's liver and kidneys have to metabolize and clear the drug before the infant's next feeding.

You also want to avoid prescribing drugs with an exceptionally long half -life, and avoid any sustained release or extended release formulations.

Those are designed to keep the drug levels in the mother's blood continuously high, which means the levels in the breast milk will stay continuously high.

Which completely defeats the purpose of timing the doses.

We have unpacked a tremendous amount of complex pharmacology from Chapter 11 today.

We really have.

To synthesize everything for your exam, remember these three core principles.

First, assume all drugs cross the placenta and enter breast milk, with lipid solubility paving the way.

Second, weeks 3 -8 of gestation represent the critical anatomical danger zone for teratogens.

And third, the baseline clinical decision always requires weighing the risk of the medication against the severe risks of leaving the maternal disease untreated.

As you process all these mechanisms and pathways, I want to leave you with a thought regarding those delayed behavioral teratogens we discussed.

The ones that cause subtle functional deficits rather than obvious physical deformities.

The ones that don't show up until school age.

Exactly.

Consider the sheer volume of over -the -counter medications, synthetic compounds, and environmental chemicals that pregnant patients interact with daily.

Because subtle learning delays or minor behavioral challenges don't manifest until a child reaches school age, it is almost impossible to trace them back to a specific gestational exposure.

It really is.

It makes you wonder, you know, how many neurodivergent challenges or subtle learning disabilities in our modern society are actually the delayed result of completely undocumented mild teratogenic exposures from decades ago.

It really underscores the profound responsibility you carry when managing medication safety.

Absolutely.

Thank you so much for joining us on this deep dive into Lane's Pharmacology.

Keep focusing on the mechanisms, trust the data, and from all of us at the Last Minute Lecture Team, we wish you the absolute best of luck on your upcoming exam.

You are going to do great.